Merops Switch to
Peptidases

Inhibitor

Family Clan Small-molecule
inhibitor SEARCHES BLAST
MEROPS

Other
information

Literature for telaprevir (S29.001 inhibitor)

Summary Structure Literature

(Topics flags: S Structure, M Mutation, I Inhibitor, V Review. To select only the references relevant to a single topic, click the link above. See explanation.)

    2019
  1. Musharrafieh,R., Ma,C., Zhang,J., Hu,Y., Diesing,J.M., Marty,M.T. and Wang,J.
    Validating enterovirus D68-2A(pro) as an antiviral drug target and the discovery of telaprevir as a potent D68-2A(pro) inhibitor
    J Virol93, e02221-18-e02221-18. PubMed  Europe PubMed DOI  I
    2. 2015
  2. Hoffmann,L., Faffe,D.S., Lima,J.F.C., Capitanio,T.A., Cabral,B.C.A., Urmenyi,T.P., Coelho,H.S.M., Rondinelli,E., Villela-Nogueira,C.A. and Silva,R.
    No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy
    BBA Clin3, 146-151. PubMed  Europe PubMed DOI  I
    3. 2014
  3. Ehrenberg,A.E., Schmuck,B., Anwar,M.I., Gustafsson,S.S., Stenberg,G. and Danielson,U.H.
    Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors
    J Enzyme Inhib Med Chem29, 868-876. PubMed  Europe PubMed DOI  I
  4. Meeprasert,A., Hannongbua,S. and Rungrotmongkol,T.
    Key binding and susceptibility of NS3/4A serine protease inhibitors against hepatitis C virus
    J Chem Inf Model54, 1208-1217. PubMed  Europe PubMed DOI  I
  5. Shang,L., Lin,K. and Yin,Z.
    Resistance mutations against HCV protease inhibitors and antiviral drug design
    Curr Pharm Des20, 694-703. PubMed  Europe PubMed DOI  M  I
    6. 2013
  6. Akuta,N., Suzuki,F., Seko,Y., Kawamura,Y., Sezaki,H., Suzuki,Y., Hosaka,T., Kobayashi,M., Hara,T., Kobayashi,M., Saitoh,S., Arase,Y., Ikeda,K. and Kumada,H.
    Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1
    J Med Virol85, 1028-1036. PubMed  Europe PubMed DOI  I
    7. 2012
  7. Matthews,S.J. and Lancaster,J.W.
    Telaprevir: a hepatitis C NS3/4A protease inhibitor
    Clin Ther34, 1857-1882. PubMed  Europe PubMed DOI  I
  8. Romano,K.P., Ali,A., Aydin,C., Soumana,D., Ozen,A., Deveau,L.M., Silver,C., Cao,H., Newton,A., Petropoulos,C.J., Huang,W. and Schiffer,C.A.
    The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
    PLoS Pathog8, e1002832-e1002832. PubMed  Europe PubMed DOI  S  I
    9. 2011
  9. Gottwein,J.M., Scheel,T.K., Jensen,T.B., Ghanem,L. and Bukh,J.
    Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses
    Gastroenterology141, 1067-1079. PubMed  Europe PubMed DOI  I
  10. Susser,S., Vermehren,J., Forestier,N., Welker,M.W., Grigorian,N., Fuller,C., Perner,D., Zeuzem,S. and Sarrazin,C.
    Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
    J Clin Virol52, 321-327. PubMed  Europe PubMed DOI  I
  11. Thompson,A.J., Locarnini,S.A. and Beard,M.R.
    Resistance to anti-HCV protease inhibitors
    Curr Opin Virol1, 599-606. PubMed  Europe PubMed DOI  I
    12. 2010
  12. Bae,A., Sun,S.C., Qi,X., Chen,X., Ku,K., Worth,A., Wong,K.A., Harris,J., Miller,M.D. and Mo,H.
    Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors
    Antimicrob Agents Chemother54, 5288-5297. PubMed  Europe PubMed DOI  I
    13. 2008
  13. Tong,X., Bogen,S., Chase,R., Girijavallabhan,V., Guo,Z., Njoroge,F.G., Prongay,A., Saksena,A., Skelton,A., Xia,E. and Ralston,R.
    Characterization of resistance mutations against HCV ketoamide protease inhibitors
    Antiviral Res77, 177-185. PubMed  Europe PubMed DOI  I
  14. Welsch,C., Domingues,F.S., Susser,S., Antes,I., Hartmann,C., Mayr,G., Schlicker,A., Sarrazin,C., Albrecht,M., Zeuzem,S. and Lengauer,T.
    Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
    Genome Biol9, R16-R16. PubMed  Europe PubMed DOI  I
  15. Zhou,Y., Bartels,D.J., Hanzelka,B.L., Muh,U., Wei,Y., Chu,H.M., Tigges,A.M., Brennan,D.L., Rao,B.G., Swenson,L., Kwong,A.D. and Lin,C.
    Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease
    Antimicrob Agents Chemother52, 110-120. PubMed  Europe PubMed DOI  S  I
    16. 2007
  16. Forestier,N., Reesink,H.W., Weegink,C.J., McNair,L., Kieffer,T.L., Chu,H.M., Purdy,S., Jansen,P.L. and Zeuzem,S.
    Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C
    Hepatology46, 640-648. PubMed  Europe PubMed DOI  I
  17. Sarrazin,C., Kieffer,T.L., Bartels,D., Hanzelka,B., Muh,U., Welker,M., Wincheringer,D., Zhou,Y., Chu,H.M., Lin,C., Weegink,C., Reesink,H., Zeuzem,S. and Kwong,A.D.
    Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
    Gastroenterology132, 1767-1777. PubMed  Europe PubMed DOI  I
  18. Zhou,Y., Muh,U., Hanzelka,B.L., Bartels,D.J., Wei,Y., Rao,B.G., Brennan,D.L., Tigges,A.M., Swenson,L., Kwong,A.D. and Lin,C.
    Phenotypic and structural analyses of hepatitis C virus NS3 protease ARG155 variants: sensitivity to telaprevir (VX-950) and interferon alpha
    J Biol Chem282, 22619-22628. PubMed  Europe PubMed DOI  I
    19. 2006
  19. Guo,Z., Prongay,A., Tong,X., Fischmann,T., Bogen,S., Velazquez,F., Venkatraman,S., Njoroge,F.G. and Madison,V.
    Computational study of the effects of mutations A156T, D168V, and D168Q on the binding of HCV protease inhibitors
    J Chem Theory Comput2, 1657-1663. PubMed  Europe PubMed DOI  I
  20. Lin,C., Kwong,A.D. and Perni,R.B.
    Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease
    Infect Disord Drug Targets6, 3-16. PubMed  Europe PubMed  V  I
  21. Lin,K., Perni,R.B., Kwong,A.D. and Lin,C.
    VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells
    Antimicrob Agents Chemother50, 1813-1822. PubMed  Europe PubMed DOI  I
  22. Perni,R.B., Almquist,S.J., Byrn,R.A., Chandorkar,G., Chaturvedi,P.R., Courtney,L.F., Decker,C.J., Dinehart,K., Gates,C.A., Harbeson,S.L., Heiser,A., Kalkeri,G., Kolaczkowski,E., Lin,K., Luong,Y.P., Rao,B.G., Taylor,W.P., Thomson,J.A., Tung,R.D., Wei,Y., Kwong,A.D. and Lin,C.
    Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease
    Antimicrob Agents Chemother50, 899-909. PubMed  Europe PubMed DOI  I
  23. [YEAR:7-2-2006]Tong,X., Guo,Z., Wright-Minogue,J., Xia,E., Prongay,A., Madison,V., Qiu,P., Venkatraman,S., Velazquez,F., Njoroge,F.G. and Malcolm,B.A.
    Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors
    Biochemistry45, 1353-1361. PubMed  Europe PubMed DOI  S  I
    24. 2005
  24. Chen,S.H. and Tan,S.L.
    Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection
    Curr Med Chem12, 2317-2342. PubMed  Europe PubMed DOI  V  I
  25. [YEAR:8-8-2005]Lin,C., Gates,C.A., Rao,B.G., Brennan,D.L., Fulghum,J.R., Luong,Y.P., Frantz,J.D., Lin,K., Ma,S., Wei,Y.Y., Perni,R.B. and Kwong,A.D.
    In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061
    J Biol Chem280, 36784-36791. PubMed  Europe PubMed DOI  I
  26. Summa,V.
    VX-950 (Vertex/Mitsubishi)
    Curr Opin Investig Drugs6, 831-837. PubMed  Europe PubMed  I
    27. 2004
  27. [YEAR:6-2-2004]Lin,C., Lin,K., Luong,Y.P., Rao,B.G., Wei,Y.Y., Brennan,D.L., Fulghum,J.R., Hsiao,H.M., Ma,S., Maxwell,J.P., Cottrell,K.M., Perni,R.B., Gates,C.A. and Kwong,A.D.
    In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms
    J Biol Chem279, 17508-17514. PubMed  Europe PubMed DOI  I

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2025 EBI
Terms of use